UAE Banking Heavyweight Joins NeOnc as Global Brain-Cancer Drug Development Advances
Key Highlights
- ➤Ali Alabedin, FAB Islamic Banking head, joins NeOnc’s Board of Directors
- ➤FAB reported AED 1.41 trillion in total assets as of June 30, 2026
- ➤NEO100 Phase 2a showed 48.9% six-month progression-free survival
- ➤NeOnc priced a $15 million registered direct offering with institutional investors
- ➤FDA scheduled NEO212 End-of-Phase 1 meeting for November 17
Expert Statements
Amir F. Heshmatpour, CEO of NeOnc Technologies Holdings
“For patients and families facing devastating brain cancers, the urgency is real. Our responsibility is to match that urgency with rigorous science and the capital needed to move clinical development forward.”
DENVER, Oct. 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings (NASDAQ: NTHI) made a powerful leadership move at a pivotal moment in its brain-cancer drug development strategy. The appointment of Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank (FAB), to NeOnc’s Board of Directors.
Alabedin brings more than three decades of international banking and executive experience to a company working to advance investigational therapies and expand its presence in the United Arab Emirates. FAB reported AED 1.41 trillion in total assets as of June 30, 2026, underscoring the scale of the financial institution from which NeOnc is drawing its new board-level expertise.
Get started
Create a free account to read the full story.